Results 151 to 160 of about 15,373 (177)

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. [PDF]

ESMO Open
Curigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N.   +23 more
europepmc   +1 more source

<i>ESR1</i>-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6. [PDF]

J Immunother Precis Oncol
Abusanad A.
europepmc   +1 more source

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling. [PDF]

Nat Commun
Fernandez KJ, Sultani G, Nobis M, Gloss B, Eshraghi L, McCart Reed AE, Alexandrou S, Lee C, Roden DL, Jones EI, Simad MH, Millar EKA, Bartonicek N, Oakes SR, Valdes-Mora F, Colino-Sanguino Y, Mok ETY, Williams HL, Kutasovic JR, Cummings MC, Stoehr J, Lee V, Harvey K, Wu S, Lakhani SR, Simpson PT, Cox TR, Ooms LM, Mitchell CA, Salomon R, Swarbrick A, Gallego-Ortega D, Lim E, Timpson P, Caldon CE.   +34 more
europepmc   +1 more source

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy. [PDF]

Front Med (Lausanne)
Peng X, Chang W.
europepmc   +1 more source

WITHDRAWN: From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer.

Breast
Stachyra P, Hernando Meliá C, López-Guerrero JA, Gavilá Gregori J, Guerrero-Zotano ÁL.   +4 more
europepmc   +1 more source

Correction Statement. [PDF]

J Manag Care Spec Pharm
europepmc   +1 more source

Fulvestrant: pharmacokinetics and pharmacology

British Journal of Cancer, 2004
Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical ...
J F R Robertson
exaly   +2 more sources

Fulvestrant (‘Faslodex’): Current and future role in breast cancer management

Critical Reviews in Oncology/Hematology, 2006
Fulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors.
Anthony Howell
exaly   +2 more sources

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways [PDF]

Oncogene, 2010
Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies.
Kenneth P Nephew, X Rao
exaly   +2 more sources